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OBJECTIVES:Multiple medical reimbursement systems exist in Europe, which may
create unequal dissemination and coverage of innovative medical devices. Even in
the setting of regularly revised systems, uptake of new technology may be delayed
leading to unequal reimbursement. METHODS: This study analyzed the 2010 geo-
graphical trends of transcatheter aortic valve implantation (TAVI) rates in 14 coun-
tries (Medtronic CoreValve System and Edwards Sapien). Implant data were gath-
ered from BIBA Medical Ltd, a UK-based provider of consulting and market analysis
services for the medical device industry. In addition demographic and economic
data were gathered from Eurostat, a statistical office of the European Union. Re-
gression techniques were used to explore the relationship between implant rate
and a number of key variables. RESULTS: In 2010, a total of 14,400 TAVI procedures
were documented providing an average country-based implant rate of 36.2 per
million/Inhabitants. A seven-fold difference in implantation rate existed between
the highest and lowest implanting countries (Germany, 77 per million/inhabitants
vs. Norway 12 per million/inhabitants). Implant rates were correlated with per-
capita GDP (r20,015), health expenditure (r20.15) and number of implanting cen-
ters in the country (r20.18). At this time, only two European countries have a
dedicated tariff for TAVI that is applicable nationwide and covers both the device
and the procedure (Germany – €34,900, France - €28,477). Differences between
country-specific tariffs depend on the method of DRG calculation. In Austria, the
TAVI tariff was made to equal that of surgical aortic valve replacement. Countries
such the UK and Italy have adopted case-by-case funding. In countries such as
Belgium and the The Netherlands TAVI is funded by the hospital-based budget.
CONCLUSIONS: Significant differences in TAVI rates exist among European coun-
tries. These observations may help us to better understand unequal patterns of
dissemination and coverage of innovative medical devices such as TAVI.
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OBJECTIVES: Expert consensus recommends follow-up (FU) for patients with pace-
makers to be performed twice annually, with implantable cardioverter defibrilla-
tors or cardiac resynchronization therapy devices four times annually. Most of the
routinely scheduled calendar based FU in-office visits do not require further action
but contribute to the consumption of limited health care resources. This model
estimates the resource use associated with in-office FU visits in Germany and the
UK (UK).METHODS:Own estimates on the number of FU visits were combined with
previously published data on frequency and distance of private and public trans-
port. Recently published data on healthcare personnel resource use were consid-
ered to model hospital resource use. Data were modeled until 2015. RESULTS: If
service providers continue the current service model of routine calendar based
in-office visits for CIED patients, about 2.23 mio visits will be needed in Germany,
and 836’000 in the UK in 2015. These visits would consume approximately 1.11 mio
hours of time in consulting rooms in Germany, and 418,000 hours in the UK. More
than 87,000 ambulance transports in Germany and 33,000 in the UK will be required
for patients attending FU visits. Patients able to use their own transport will drive
about 287 mio kilometers in Germany and 28 mio kilometers in the UK. Workload
for physicians, nurses and technicians will reach 1.1 mio hours in Germany, and
406,000 hours in the UK, most of them being provided by physicians. These esti-
mates do not yet include unscheduled and emergency services for CIED patients.
CONCLUSIONS: The increasing number of in-office FU visits will continue to place
a heavy burden on primarily cardiology service providers but also on patients.
Technologies such as BIOTRONIK’s Home Monitoring can assist hospitals in han-
dling the increasing service demand, free patients from unnecessary travel burden,
and ensure adherence to FU.
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OBJECTIVES: Cost of illness analysis of breast cancer in Austria using mainly Aus-
trian billing data from intramural and extramural medical treatment based on data
from 2006/07 for treatment and degree of severity evaluation. Regarding this proj-
ect a detailed treatment course classification has to be realized to evaluate the
costs and patient ways in Austrian health system. METHODS: Main strategy of the
project is the combination of data samples detected by Austrian cancer registry and
billing data of intramural and extramural single person datasets in combination
with intake data of medication for each patient. By combining the recorded data
from national statistics, including TNM-classification of each new breast cancer
case, and the ICD10-diagnoses, as well as medical individual services, results in
classification of breast carcinoma on single person level are achieved. For separa-
tion of drug treatment concerning chronical diseases versus cancer indicated drug
administration, the half year time span before the first mamma carcinoma detec-
tion and the year afterwards is analyzed separately. Special medication groups are
assessed in detail and inclusion/exclusion – criteria for costs and treatment are
defined. RESULTS: Based on this identification an alternative subsumption of new
detected carcinoma in six groups (hormone receptor positive, Her 2 positive, hor-
mone receptor positive and Her 2 positive, triple negative, metastasizing mamma
carcinoma, early stage mamma carcinoma without chemo therapy in course of
treatment) is defined.CONCLUSIONS:This classification leads to better insights for
cost evaluation representing the state of the art in Austria. This strategy also leads
to better overall reliability because the margin of uncertainty of the parameters can
be reduced significantly.
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OBJECTIVES: To review reports of anaphylactoid reactions from gadolinium prod-
ucts (GPs) and iodinated contrast media (ICMs) and to compare events, outcomes,
and signals associated with different GPs. METHODS: We reviewed ARs in the FDA
Adverse Event Reporting System (AERS) and compared reports for GPs and ICMs.
We searched FDA-AERS using all reaction terms for ARs linked with GPs and, sep-
arately, ICMs. We compared demographics, outcomes, and types of reactions be-
tween GPs and ICMs. We compared signal detection results for each GP using
proportional reporting ratios (PRRs) and 95% confidence intervals (CI). RESULTS:
Through March 2010, there were 494 and 2,533 reports for GPs and ICMs, respec-
tively. The data are not confluent since ICM usage preceded GP usage (first ICM
event date: 1943, received by FDA: 1969; first GP event date: 1969, received by FDA
1998). Mean ages ( standard deviation) were 49.118.0, and 5718.5, and % male/
female were 38%/59% and 40%/43% for GPs and ICMs, respectively. The ARs for GPs
and ICMs were serious in 91.7%/97.5% and fatal in 7.5%/13.9%, respectively. Propor-
tions of reports and PRRs (CI) for linear GPs were: gadopentetate dimeglumine 
45.3%, 5.03 (4.34-5.71), gadobenate dimeglumine 25.9%, 11.41 (9.67-13.46). For the
other linear GPs, gadodiamide was reported in 7.9% and gadoversetamide in 0.1%,
but the number of cases of use of the agents alone were too small to determine PRR.
Gadoteridol, a cyclic GP, was reported in 18.2% of cases with a PRR of 5.27 (4.30-6.45).
Overall, PRRs were indicative of safety signals for both GPs and ICMs, 5.9, (5.4-6.4),
7.4 (CI: 7.1-7.7), respectively. CONCLUSIONS: FDA-AERS data indicate that GP-as-
sociated ARs generate a safety signal comparable to ICMs. Although over 80% of
GP-associated ARs were with linear GPs, there was a significant safety signal for
one macrocyclic structure GP as well as two linear structure GPs.
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OBJECTIVES: The use of home dialysis modalities such as peritoneal dialysis and
home haemodialysis varies across Europe and North America from today 5% in
Germany to 28% in Denmark. These differences have often been attributed to re-
imbursement and renal care organization factors. This analysis was undertaken to
quantify the strength of association of potential factors influencing usage of home
dialysis modalities with the intent to later facilitate evidence based policy choices.
METHODS: A 4-pillar framework including 8 different factors (home target, reim-
bursement level, payment flow, pre-dialysis education, assisted dialysis, home
guideline/policy, incentives for home, monitoring/planning tool) was postulated to
explain the variation in home dialysis usage across countries. A semi-quantitative
scoring algorithm was developed and used to rate the renal care organization of 12
European countries, Canada, and the USA based on publicly available information.
A regression analysis was used to explore the relationship between the score and
the use of home dialysis modalities as retrieved from the latest available renal
registry reports. The most significant factors were identified by analysis of
variance. RESULTS: A significant (r20.694; p0.001) correlation was found be-
tween the total score and home dialysis usage. Countries like Denmark and Swe-
den achieving a score of 5 have a 26-28% usage of home modalities. In comparison,
Germany had a score of 2 and 5% of dialysis patients are on home modalities.
Three factors were especially significant: well funded and independent pre-dialysis
education (p0.001), clinical guideline/policy favouring home modalities
(p0.002), and (absence of) provider-driven demand (p0.035). CONCLUSIONS:
The 4-pillar framework appears to be useful to identify gaps in a country renal care
policy and decide on further actions to be taken when intending to increase usage
of home dialysis modalities. Actions to implement/correct pre-dialysis education,
clinical guideline/policy favouring home modalities and (absence of) provider-
driven demand should probably be prioritized.
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